Anocca, a Södertälje, Sweden-based cell therapy biotechnology company, received €25M in Venture Debt.
The European Investment Bank made the financing.
The company intends to use the funds to move T-cell immunotherapies towards clinical trials in a solid tumour indication.
Led by CEO Reagan Jarvis, Anocca is using technology to engineer next generation T-cell immunotherapies for the treatment of solid tumours. The company is building libraries of novel T-cell immunotherapies that specifically target difficult to treat cancers and will be moving into clinical trials in 2024. Alongside oncology, proprietary technologies are being applied to the development of vaccines and treatments for autoimmune diseases.
Founded in 2014, Anocca is led by an experienced management team that has raised EUR 100 million in funding from leading Nordic investors.
FinSMEs
21/12/2022